Objectif
Despite dramatic advances in molecular and imaging technologies and nearly 1 5,000 articles on schizophrenia and depression (S&D) there are few novel treatments. We think this is because of three major “bottle-necks”: a lack of etiologically-driven or pathophysiologically-accurate animal models; a lack of tests that provide indication of efficacy in healthy volunteers; and the reliance of clinical trials on DSM categories which provide a collection of biologically heterogeneous patients. Our broad working hypothesis is that a focus on cross-species endophenotypes, testing in healthy volunteers and finding biologically-homogenous groups of patients will overcome existing limitations in target identification, early triage and clinical trials. To implement this idea six leading European institutions and two SMEs will partner with the EFPIA to: a) develop animal models that carry confirmed genetic risks, and in these animals to focus on cross-species endophenotypes (e.g. cognitive function, electrophysiology) to facilitate new drug discovery; b) validate the use of fMRI-based endopheno types in genetically-selected healthy volunteers and patients as early and surrogate markers for efficacy; and to combine this with PET approaches for plasma-kinetics to brain-dynamics modelling to provide guidance regarding optimal clinical trial design; and c) identify pharmacogenetic and multi-omic biomarkers that can be used to stratify patients within an umbrella DSM-diagnosis, thus allowing for ) targeted clinical trials, individualized treatment and back-translation of subgroup-specific biomarkers into preclinical drug discovery. To increase the chance of a breakthrough we will implement new analytical approaches (e.g. support vector machine learning algorithms; Bayesian analyses) and will
actively collaborate with other ongoing international efforts (esp. the Biomarkers Consortium, NIH).
Champ scientifique
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesbiological sciencesneurobiologycognitive neuroscience
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesclinical medicinepsychiatryschizophrenia
- natural sciencescomputer and information sciencesartificial intelligencemachine learning
Thème(s)
Appel à propositions
IMI-JU-01-2008
Voir d’autres projets de cet appel
Régime de financement
JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)Coordinateur
2500 Valby
Danemark
Voir sur la carte
Participants (19)
WC2R 2LS London
Voir sur la carte
17177 Stockholm
Voir sur la carte
CB2 1TN Cambridge
Voir sur la carte
68159 Mannheim
Voir sur la carte
28006 Madrid
Voir sur la carte
M13 9PL Manchester
Voir sur la carte
CB4 0WS Cambridge
Voir sur la carte
Participation terminée
101 Reykjavik
Voir sur la carte
80333 Muenchen
Voir sur la carte
Participation terminée
151 85 Sodertaelje
Voir sur la carte
RG21 4FA Basingstoke
Voir sur la carte
2340 Beerse
Voir sur la carte
4056 Basel
Voir sur la carte
02200 Espoo
Voir sur la carte
CT13 9NJ Sandwich
Voir sur la carte
4070 Basel
Voir sur la carte
91190 GIF-SUR-YVETTE
Voir sur la carte
52900 Ramat Gan
Voir sur la carte
65205 Wiesbaden
Voir sur la carte